374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors

• Afshin Dowlati,
• Andrea Bullock,
• Susanna Ulahannan,
• Manish Patel,
• Shubham Pant,
• Amita Patnaik,
• Marsha Crochiere,
• Devalingam Mahalingam,
• Wael Harb,
• Haider Mahdi,
• Manmeet Ahluwalia,
• Patrick Wen,
• Mary Mulcahy,
• Robert Guttendorf,
• Lou Vaickus,
• Suming Wang,
• Melanie Vincent,
• Michael Cieslewicz,
• Jing Watnick

Affiliations

Afshin Dowlati

7Case Western, Cleveland, OH, USA

Andrea Bullock

8Beth Israel Deaconess Hospital, boston, MA, USA

Susanna Ulahannan

4University of Oklahoma Health Sciences C, OKC, OK, USA

Manish Patel

6Florida Cancer Specialists, Sarasota, FL, USA

Shubham Pant

10MD Anderson, Houston, TX, USA

Amita Patnaik

3South Texas Accelerated Research Therape, San Antonio, TX, USA

Marsha Crochiere

13Vigeo Therapeutics, Cambridge, MA, USA

Devalingam Mahalingam

1Northwestern University Medical School, Chicago, IL, USA

Wael Harb

2Horizon Oncology Center, Lafayette, IN, USA

Haider Mahdi

5Cleveland Clinic, Cleveland, OH, USA

Manmeet Ahluwalia

5Cleveland Clinic, Cleveland, OH, USA

Patrick Wen

9Dana Farber Cancer Institute, Boston, MA, USA

Mary Mulcahy

1Northwestern University Medical School, Chicago, IL, USA

Robert Guttendorf

11Aclairo Pharmaceutical Development Group, Vienna, VA, USA

Lou Vaickus

12aktaPD/Vigeo Therapeutics, Boston/Cambridge, MA, USA

Suming Wang

13Vigeo Therapeutics, Cambridge, MA, USA

Melanie Vincent

13Vigeo Therapeutics, Cambridge, MA, USA

Michael Cieslewicz

13Vigeo Therapeutics, Cambridge, MA, USA

Jing Watnick

13Vigeo Therapeutics, Cambridge, MA, USA